149 related articles for article (PubMed ID: 25083424)
1. Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.
Gong L; Chen P; Liu X; Han Y; Zhou Y; Zhang W; Li H; Li C; Xie J
Gland Surg; 2012 May; 1(1):25-32. PubMed ID: 25083424
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
Prasad PA; Raju K
J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
5. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
8. The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression.
Salajegheh A; Dolan-Evans E; Sullivan E; Irani S; Rahman MA; Vosgha H; Gopalan V; Smith RA; Lam AK
Exp Mol Pathol; 2014 Apr; 96(2):212-8. PubMed ID: 24530443
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
10. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.
Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A
J Res Med Sci; 2016; 21():49. PubMed ID: 27904595
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma.
Lee YM; Lee JB
J Int Med Res; 2013 Jun; 41(3):825-34. PubMed ID: 23569038
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.
Huang L; Wang X; Huang X; Gui H; Li Y; Chen Q; Liu D; Liu L
Oncol Lett; 2018 Apr; 15(4):4269-4277. PubMed ID: 29541194
[TBL] [Abstract][Full Text] [Related]
13. Hyalinizing trabecular tumor and papillary carcinoma of the thyroid.
Zhu H; Qi JP; Wang YW; Song YJ; Zhang ZY
Chin Med J (Engl); 2010 Oct; 123(20):2832-5. PubMed ID: 21034592
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.
Saleh HA; Feng J; Tabassum F; Al-Zohaili O; Husain M; Giorgadze T
Cytojournal; 2009 Sep; 6():18. PubMed ID: 19826479
[TBL] [Abstract][Full Text] [Related]
15. Relationships between Lymph Node Metastasis and Expression of CD31, D2-40, and Vascular Endothelial Growth Factors A and C in Papillary Thyroid Cancer.
Lee SH; Lee SJ; Jin SM; Lee NH; Kim DH; Chae SW; Sohn JH; Kim WS
Clin Exp Otorhinolaryngol; 2012 Sep; 5(3):150-5. PubMed ID: 22977712
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma.
Liu Z; Li X; Shi L; Maimaiti Y; Chen T; Li Z; Wang S; Xiong Y; Guo H; He W; Liu C; Nie X; Zeng W; Huang T
Int J Clin Exp Med; 2014; 7(8):2304-8. PubMed ID: 25232425
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
18. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
19. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
